New Drug: Glofitamab for Large B Cell Lymphoma
Study
Phase 2 study |
Relapsed or refractory DLBCL, transformed follicular lymphoma, high-grade B-cell lymphoma, or primary mediastinal large B-cell lymphoma |
Obinituzumab and Glofitamab (n = 155) |
Efficacy
ORR: 52% |
CR: 39% |
1-yr PFS: 37% |
mOS: 4.9 mos |
1-yr OS: 50% |
Safety
Any glofitamab-related grade ≥3 AEs: 42% |
N Engl J Med 2022; 387:2220-2231
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
http://doi.org/ 10.1056/NEJMoa2206913
Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023
